Zelanna Goldberg

2.0k total citations
60 papers, 1.4k citations indexed

About

Zelanna Goldberg is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Zelanna Goldberg has authored 60 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 28 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Zelanna Goldberg's work include Lung Cancer Treatments and Mutations (21 papers), Colorectal Cancer Treatments and Studies (10 papers) and Effects of Radiation Exposure (9 papers). Zelanna Goldberg is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Colorectal Cancer Treatments and Studies (10 papers) and Effects of Radiation Exposure (9 papers). Zelanna Goldberg collaborates with scholars based in United States, China and Spain. Zelanna Goldberg's co-authors include Bruce E. Lehnert, Pasi A. Jänne, Ian W. Taylor, Joseph O’Connell, Mark G. Kris, Robin L. Stern, Giuseppe Giaccone, D. Ross Camidge, David R. Gandara and Tony Mok and has published in prestigious journals such as Journal of Clinical Oncology, The EMBO Journal and Cancer Research.

In The Last Decade

Zelanna Goldberg

58 papers receiving 1.4k citations

Peers

Countries citing papers authored by Zelanna Goldberg

Since Specialization

Citations

This map shows the geographic impact of Zelanna Goldberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zelanna Goldberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zelanna Goldberg more than expected).

Fields of papers citing papers by Zelanna Goldberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zelanna Goldberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zelanna Goldberg. The network helps show where Zelanna Goldberg may publish in the future.

Co-authorship network of co-authors of Zelanna Goldberg

This figure shows the co-authorship network connecting the top 25 collaborators of Zelanna Goldberg. A scholar is included among the top collaborators of Zelanna Goldberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zelanna Goldberg. Zelanna Goldberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open label clinical trial 2025 ·Communications Medicine ·(unknown), (unknown), Shigeki J. Miyake‐Stoner, Brandon Essink, (unknown), Jessica L. Sparks, Andrew J. Geall, Nathaniel Wang, Zelanna Goldberg, Parinaz Aliahmad	0
2	High Peak-Power Pulse Amplification in Very-Large Mode-Area Er-doped Amplifiers 2021 ·Conference on Lasers and Electro-Optics ·Jeffrey W. Nicholson, A. DeSantolo, (unknown), (unknown), P. Wisk, Eric M. Monberg, (unknown), (unknown), Ming Niu, Zelanna Goldberg	2
3	Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors 2015 ·Annals of Oncology ·Mark G. Kris, D. Ross Camidge, Giuseppe Giaccone, Toyoaki Hida, Bob T. Li, Joseph O’Connell, Ian W. Taylor, (unknown), Maria E. Arcila, Zelanna Goldberg, Pasi A. Jänne	221
4	Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers 2015 ·The Journal of Clinical Pharmacology ·Ana Ruiz-Garcı́a, Joanna C. Masters, (unknown), Robert R. LaBadie, Yali Liang, (unknown), (unknown), (unknown), Zelanna Goldberg, Carlo L. Bello	20
5	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial 2014 ·The Lancet Oncology ·Suresh S. Ramalingam, Pasi A. Jänne, Tony Mok, Kenneth J. O’Byrne, Michael Boyer, Joachim von Pawel, Adam Płużański, Mikhail Shtivelband, Lara Iglesias Docampo, Jaafar Bennouna, Hui Zhang, Jane Liang, Jim Doherty, Ian W. Taylor, (unknown), Zelanna Goldberg, Joseph O’Connell, Luis Paz‐Ares	111
6	Phase 3 Randomized Study (ARCHER 1050) of 1st-Line Dacomitinib vs Gefitinib for Advanced NSCLC with EGFR Mutation(S) 2013 ·Annals of Oncology ·Tony Mok, Kazuhiko Nakagawa, Rafael Rosell, Yi‐Long Wu, Carl W. Trygstad, Robert L. Capizzi, (unknown), Zelanna Goldberg, (unknown), Vladan Antic	4
7	Assessing probe-specific dye and slide biases in two-color microarray data 2008 ·BMC Bioinformatics ·Ruixiao Lu, Geun-Cheol Lee, Michael A. Shultz, Chris Dardick, Ki‐Hong Jung, (unknown), Yi Jia, Robert H. Rice, Zelanna Goldberg, Patrick S. Schnable, Pamela C. Ronald, David M. Rocke	10
8	A Phase II Study of Paclitaxel, Carboplatin, and Radiation with or without Surgery for Esophageal Cancer 2007 ·Journal of Thoracic Oncology ·Henry E. Wang, Janice Ryu, David R. Gandara, Richard J. Bold, Shiro Urayama, Michael Tanaka, Zelanna Goldberg, David M. Follette, Samir Narayan, Derick Lau	33
9	Transient Genome-Wide Transcriptional Response to Low-Dose Ionizing Radiation In Vivo in Humans 2007 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), David M. Rocke, Jian Dai, (unknown), (unknown), Robin L. Stern, Jöerg Lehmann, Christine L. Hartmann Siantar, Zelanna Goldberg	35
10	Optimized Methodology for Sequential Extraction of RNA and Protein from Small Human Skin Biopsies 2006 ·Journal of Investigative Dermatology ·(unknown), (unknown), (unknown), Robin L. Stern, Jöerg Lehmann, Zelanna Goldberg	30
11	Use of benchmark dose–volume histograms for selection of the optimal technique between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy in prostate cancer 2006 ·International Journal of Radiation OncologyBiologyPhysics ·Chunhui Luo, Claus Chunli Yang, Samir Narayan, Robin L. Stern, Julian Perks, Zelanna Goldberg, Janice Ryu, James A. Purdy, Srinivasan Vijayakumar	23
12	Dosimetry for Quantitative Analysis of the Effects of Low-Dose Ionizing Radiation in Radiation Therapy Patients 2006 ·Radiation Research ·Jöerg Lehmann, Robin L. Stern, (unknown), David M. Rocke, (unknown), Gregory E. Jones, Michelle Arnold, Christine L. Hartmann Siantar, Zelanna Goldberg	13
13	Dosimetry for quantitative analysis of low dose ionizing radiation effects on humans in radiation therapy patients 2004 ·Radiation Research ·Jöerg Lehmann, Robin L. Stern, T.P. Daly, (unknown), Gregory E. Jones, (unknown), (unknown), Zelanna Goldberg	2
14	Film dosimetry in the peripheral region using multiple sensitometric curves 2004 ·Medical Physics ·Robin L. Stern, (unknown), (unknown), Jöerg Lehmann, Zelanna Goldberg	5
15	Enhancement of Radiation Cytotoxicity by UCN-01 in Non-small Cell Lung Carcinoma Cells 2004 ·Radiation Research ·Philip C. Mack, (unknown), (unknown), David R. Gandara, Paul H. Gumerlock, Zelanna Goldberg	12
16	Survival and cell cycle kinetics of human prostate cancer cell lines after single- and multifraction exposures to ionizing radiation 2004 ·International Journal of Radiation OncologyBiologyPhysics ·Susan Scott, Paul H. Gumerlock, Laurel Beckett, Yueju Li, Zelanna Goldberg	23
17	Concurrent Chemoradiation Strategies in the Management of Unresectable Stage III non—small-Cell Lung Cancer 2002 ·Clinical Lung Cancer ·Primo N. Lara, Zelanna Goldberg, Angela M. Davies, Derick Lau, David R. Gandara	2
18	Current and future therapeutic approaches in locally advanced (stage III) non[ndash ]small cell lung cancer 2002 ·Seminars in Oncology ·Angela M. Davies, David R. Gandara, Primo N. Lara, Zelanna Goldberg, Peter Roberts‎, Derick Lau	4
19	An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin 2001 ·International Journal of Radiation OncologyBiologyPhysics ·Zelanna Goldberg, James Evans, Geoffrey W. Birrell, J. Martin Brown	12
20	Role of a DT-diaphorase mutation in the response of anal canal carcinoma to radiation, 5-fluorouracil, and mitomycin C 1998 ·International Journal of Radiation OncologyBiologyPhysics ·Zelanna Goldberg, Bernard Cummings, William Chapman, Henry J. Klamut, Andrew M. Rauth	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact